Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
- The Jefferies 2019
London Healthcare Conferenceon Thursday, November 21, 2019at 3:20 p.m.Greenwich Mean Time ( 10:20 a.m. Eastern Time)
Piper Jaffray31st Annual Healthcare Conference in New Yorkon Wednesday, December 4, 2019at 3:30 p.m. Eastern Time
A live webcast of each presentation can be accessed in the News & Events section of Milestone's website at www.milestonepharma.com. An archived replay of each webcast will be available on the same website for approximately 30 days following the presentation.
Milestone is a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. Etripamil is a novel, potent and short-acting calcium channel blocker designed by Milestone and being developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of PSVT as they occur. Milestone is actively recruiting patients for a Phase 3 clinical trial of etripamil for the treatment of PSVT. Top-line data from the phase 3 pivotal efficacy trial (NODE-301) is expected in the middle of the first half of 2020.
View original content to download multimedia:http://www.prnewswire.com/news-releases/milestone-pharmaceuticals-to-present-at-upcoming-investor-conferences-300957945.html